The world's most advanced psychedelic-assisted therapy trial has confirmed positive findings in the second Phase 3 trial of MDMA-assisted therapy for PTSD.
Since the final participant for this MAPP2 was treated on November 17, 2022, the database has been locked and is being analyzed. This study is our second Phase 3 trial of MDMA-assisted therapy for posttraumatic …
MAPS Public Benefit Corporation (MAPS PBC) has announced that the final participant in the second Phase 3 trial of psychedelic-assisted therapy, A Multi-Site Phase 3 Study of MDMA-Assisted Therapy for …
FOR IMMEDIATE RELEASE: May 9, 2022 The second, confirmatory Phase 3 trial of MDMA-assisted therapy for PTSD is now fully enrolled at 13 sites in the United States and Israel Completion of enrollment on …
On March 22, 2022, all study sites have met the criteria to provide treatment in the cross-over extension study for MAPS-sponsored Phase 3 trials of MDMA-assisted therapy for posttraumatic stress disorder …
On February 3, our Phase 3 study site for MDMA-assisted psychotherapy for PTSD in Tel Hashomer, Israel, officially opened for phone screenings and informed consent visits. Led by Principal Investigator …
Our second Phase 3 clinical trial of MDMA-assisted therapy for PTSD is well underway, with enrollment of more than two-thirds of the participants needed to complete the study. We have also begun our long …
We are currently seeking research volunteers for our second Phase 3 clinical trial of MDMA-assisted therapy for PTSD. We’ve already accrued about 57 of the 100 subjects needed so potential volunteers …
We are currently seeking research volunteers for our second Phase 3 clinical trial of MDMA-assisted therapy for PTSD. Volunteers must have PTSD and live in an area close to a study site. People of color …
We are currently seeking research volunteers for our second Phase 3 clinical trial of MDMA-assisted therapy for PTSD. Volunteers must have PTSD and live in an area close to a study site. Volunteers will …
We are currently seeking research volunteers for our second Phase 3 clinical trial of MDMA-assisted therapy for PTSD. Volunteers must have PTSD and live in an area close to a study site. Volunteers will …